All In Biotech

Free tool

FAERS Monitor: Orserdu

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 217639 or its brand name (Orserdu, Elacestrant Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

7,181

Serious

2,423

34% of reports

Hospitalization

906

Death reported

553

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • nausea1,512
  • fatigue1,130
  • disease progression783
  • vomiting694
  • diarrhoea566
  • death520
  • drug ineffective491
  • constipation408
  • product dose omission issue382
  • decreased appetite377
  • pain374
  • arthralgia342
  • asthenia249
  • dyspepsia240
  • abdominal discomfort238

Reports by year received

View as table
YearReports
20202
20212
20221
20233,022
20243,662
2025330
2026162

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,978 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
disease progressionSignal78319.518.313,714
dyspepsiaSignal2407.26.31,269
nauseaSignal1,5125.65.45,927
constipationSignal4085.55.01,506
decreased appetiteSignal3774.84.31,127
vomitingSignal6944.34.01,811
fatigueSignal1,1304.34.02,915
abdominal discomfortSignal2384.23.7572
product dose omission issueSignal3823.83.5798
diarrhoeaSignal5662.62.4558
arthralgiaSignal3422.42.2286
asthenia2491.91.7114
pain3741.81.6132
death5201.81.6180
drug ineffective4911.11.04

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.